Concern of brain gadolinium deposition is resulting in a switch to macrocyclic MR contrast agents in pediatric hospitals.
Macrocyclic gadolinium-based contrast agents (GBCA) are increasingly preferred to a linear GBCA in pediatric hospitals, according to a study published in the journal Pediatric Radiology. Researchers from Northwestern University in Chicago, Ill., and the University of Arizona in Phoenix sought to determine how pediatric hospitals were using gadolinium, as well as learn more about the knowledge base among radiologists and referring providers regarding GBCAs and brain gadolinium deposition. The researchers sent out surveys to 5,390 physicians in various pediatric professional societies between January 2016 and March 2016. The groups included the Society of Chairs of Radiology in Children's Hospitals (SCORCH), the Society for Pediatric Radiology, the Pediatric Endocrine Society, as well as a group of pediatric neuro-oncology attending physicians, pediatric neurology attending physicians, and pediatric infectious disease program directors. The results showed 80 percent of surveyed pediatric hospitals used macrocyclic contrast agents and within the last year, 58 percent switched their agent, most commonly to gadoterate meglumine. The most common reason given was concern about brain gadolinium deposition. Another 23 percent of hospitals were considering switching. Of these hospitals, 83 percent would switch to gadoterate meglumine. The most common reasons given for the switch were brain gadolinium deposition and safety. Radiologists were more aware of brain gadolinium deposition than non-radiologist physicians (87 percent versus 26 percent). Radiologists and referring providers both expressed similar levels of concern (95 percent and 89 percent). In addition, 12 percent of radiologists and 2 percent of referring providers reported patients asking about brain gadolinium deposition. Radiologists were significantly more comfortable addressing patient inquiries than referring pediatric physicians (48 percent versus 6 percent). The number of MRIs requested by referring pediatric physicians correlated with their knowledge of brain gadolinium deposition, contrast agent used by their hospital, and comfort discussing brain gadolinium deposition with patients. The researchers concluded many pediatric hospitals have switched to or plan to switch to a more stable macrocyclic MR contrast agent, most commonly gadoterate meglumine based on the discovery of the presence of brain gadolinium deposition. “Despite this, there is need for substantial further education of radiologists and referring pediatric providers regarding GBCAs and brain gadolinium deposition,” they wrote.
Emerging AI Algorithm Shows Promise for Abbreviated Breast MRI in Multicenter Study
April 25th 2025An artificial intelligence algorithm for dynamic contrast-enhanced breast MRI offered a 93.9 percent AUC for breast cancer detection, and a 92.3 percent sensitivity in BI-RADS 3 cases, according to new research presented at the Society for Breast Imaging (SBI) conference.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
Clarius Mobile Health Unveils Anterior Knee Feature for Handheld Ultrasound
April 23rd 2025The T-Mode Anterior Knee feature reportedly offers a combination of automated segmentation and real-time conversion of grayscale ultrasound images into color-coded visuals that bolster understanding for novice ultrasound users.